Pacira BioSciences shares are trading lower after the FDA approved a generic version of Exparel.
Portfolio Pulse from Benzinga Newsdesk
Pacira BioSciences shares are trading lower after the FDA approved a generic version of Exparel.
July 02, 2024 | 7:18 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Pacira BioSciences shares are trading lower following the FDA's approval of a generic version of Exparel, which is likely to increase competition and impact Pacira's market share and revenues.
The approval of a generic version of Exparel by the FDA introduces direct competition to Pacira BioSciences' product, likely leading to a decrease in market share and revenues for Pacira. This negative impact is reflected in the immediate drop in share price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100